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Abstract
Background—Minority race/ethnicity is generally associated with antiretroviral therapy
nonadherence in US-based studies. Limitations of the existing literature include small samples,
subjective adherence measures, and inadequate control for potential confounders such as mental
health and substance use, which have been consistently associated with poorer adherence.
Methods—Individual-level data were pooled from 13 US-based studies employing electronic
drug monitoring to assess adherence. Adherence was operationalized as percent of prescribed
doses taken from the first 12 (monthly) waves of data in each study. Depression symptoms were
aggregated from several widely used assessments, and substance use was operationalized as any
use of cocaine/stimulants, heroin/opiates, ecstasy, hallucinogens, or sedatives in the 30–365 days
preceding baseline.
Results—The final analytic sample of 1809 participants ranged in age from 18 to 72 years and
was 67% male. Participants were 53% African American, 14% Latino, and 34% White. In a
logistic regression adjusting for age, gender, income, education, and site, race/ethnicity was
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significantly associated with adherence (P < 0.001) and persisted in a model that also controlled
for depression and substance use (P < 0.001), with African Americans having significantly lower
adherence than Latinos [odds ratio (OR) = 0.72, P = 0.04] and whites (OR = 0.60, P < 0.001).
Adherence did not differ between whites and Latinos (OR = 0.84, P = 0.27).
Conclusions—Racial/ethnic differences in demographics, depression, and substance abuse do
not explain the lower level of antiretroviral therapy adherence in African Americans observed in
our sample. Further research is needed to explain the persistent disparity and might examine
factors such as mistrust of providers, health literacy, and inequities in the health care system.
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INTRODUCTION
Antiretroviral therapy (ART) has led to marked reductions in mortality and morbidity
among HIV-positive individuals, yet from the outset optimal adherence to prescribed
regimens has remained essential to its success.1,2 Identifying subgroups at risk for
nonadherence and tailoring treatment to address their needs or to otherwise address factors
causing the disparities may help optimize treatment success.
Racial/ethnic minority group status has been linked repeatedly to lower levels of ART
adherence and viral suppression among HIV-positive cohorts in the United States.3–10 For
example, in a large sample of patients enrolled in an integrated health care system (thus
equalizing access to care), Silverberg et al11 reported that adjusted mean refill adherence,
operationalized as the percentage of days with antiretroviral (ARV) medication coverage
between refills, was lower among patients who were African American (64%) or Hispanic
(65%) compared with white (70%). Based on data from the Multicenter AIDS Cohort Study,
Lee et al12 reported that after controlling for site, age, financial difficulties, popper use,
crack use, and viral load, Hispanics were 2.2 (95% CI: 1.5 to 3.2) and African Americans
were 1.4 (95% CI: 1.1 to 1.8) times more likely than whites to report having taken less than
100% of all their prescribed HIV medication doses over the previous 4 days.
Most prior studies have important methodological limitations. Some have small samples,
which limits statistical power, and others use only self-reports of adherence, which can
overestimate actual adherence. In addition, few prior studies adequately controlled for
potential confounders known to be important in racially and ethnically diverse populations
including depression13 and substance use.14–16 Psychiatric disorder and drug dependence
are highly prevalent among individuals with HIV, with positive screening for each as high at
50% in the HIV Cost and Services Utilization Study.17 Although data on racial/ethnic
differences in these potential barriers to adherence are mixed,11,17,18 racial/ethnic minority
groups in the United States seem to have less access to high quality treatment for these
conditions, which may exacerbate their effects on nonadherence.19,20
Most of the studies examining racial/ethnic difference in adherence included African
Americans, with smaller numbers of and fewer comparisons with Latinos. Those including
Latinos generally showed them to be at greater risk for nonadherence than Whites.21
Waldrop-Valverde et al22 concluded that there is no consensus on whether African
Americans adhere worse than individuals from other racial/ethnic groups, with demonstrated
differences possibly due to adherence measurement error or comorbidities such as
depression and substance abuse.
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In the present study, we analyzed data from the Multi-site Adherence Collaboration on HIV
(MACH14) to examine the association of race/ethnicity to adherence. Advantages of
MACH14 were that adherence was measured electronically, the population was large
relative to most prior studies, African Americans and Latinos were well represented, and we
were able to control for key potential confounders including depressive symptomatology and
substance use.
METHODS
Data Source
Data came from a National Institute of Mental Health–funded project combining data from
16 studies of electronically monitored ART adherence conducted at 14 sites in the United
States.23 Demographic, psychosocial, and biological data assessed across the studies were
combined in the pooled data via the creation of new variables incorporating data across
studies. The present study focused on 13 studies conducted at 11 research sites, excluding
the 3 studies that collected no data on income or education level. Only individuals self-
identifying as African American, Latino, or white were included. Prospective predictors
were taken from the baseline assessment (ie, the first assessment point at which they were
collected). As indicated below, we used a missing indicator approach to deal with missing
data.24
Measures
Demographic Characteristics—These included site, gender, age in years, income
(percent reporting an annual household income of more than $10,000), and education level
(percent graduating high school). Race/ethnicity was determined by self-identification as
white, African American, or Latino.
ART Adherence—Adherence was measured with the Medication Event Monitoring
System (MEMS; http://www.aardex.ch), a pill bottle and cap that electronically records the
date and time of each opening as a presumptive dose. The adherence outcome was
operationalized as percent adherence across the entire period the participant was observed,
up to 12 months. Specifically, adherence was calculated separately for each of the first 12
months after a participant’s baseline assessment. Each month was defined as a 4-week
period with the percent adherence calculated across monitored ARV medications. Percent
ART adherence was calculated as the number of doses taken divided by the total number of
doses prescribed during each 4-week period. An overall index of ART adherence was
derived by averaging adherence for each of the monthly intervals during which a participant
was monitored. For studies that followed participants for less than 12 months, the adherence
outcome reflected the average for the monitored months.
Depression
Different measures of depression were administered across studies as follows: 4 used the
Beck Depression Inventory version II25; 1 used the original version of the Beck Depression
Inventory26; 3 used the Center for Epidemiological Studies Depression Scale27; 2 used the
depression subscale of the Brief Symptom Inventory28; and 1 used the Primary Care
Screener for Affective Disorders.29 To aggregate data from these different scales, we first
calculated standardized Z scores (ie, subtracting the normative—not the study—mean of the
scale from the sum of the scale items in the particular study and then dividing by the
normative standard deviation).30 This approach, which we used successfully in a prior study
(Wagner et al31) circumvents the potential bias of participants in each study receiving Z
scores based on their level of depression relative to the other participants in that particular
study rather than the wider population.
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The participant’s Z score was denoted as missing if more than half of the depression scale
items were missing for that individual. Based on this continuous measure, we determined a
3-category diagnosis of “minimal, mild/moderate, or severe” depression, reflecting
established diagnostic cutoffs for each depression measure. A fourth category of “missing”
was included for participants who were administered a depression scale without diagnostic
cut-offs or for whom a depression score was not available.
Substance Use—Because multiple drug use is common and combining a range of
substances used may create a more reliable predictor than individual drug use indicators,32
we computed a categorical indicator encompassing any use of the following substances:
cocaine/stimulants, heroin/opiates, ecstasy, hallucinogens, or sedatives. Alcohol use was not
included in the indicator as drinking to intoxication was assessed only at a single site, so it
was not possible to differentiate problem drinking. The time frame of substance use varied
by study and ranged from the last 30 to 365 days. An additional category of “missing” was
included for participants without substance use data.
Statistical Analysis
Descriptive analyses were performed to identify means, standard deviations, and bivariate
correlations of the demographic, depression, substance use, and adherence variables. We
used logistic regression in combination with robust standard error correction to evaluate
medication adherence as a continuous variable between 0 and 1. This approach has been
previously recommended for the analysis of continuous percentage data.33,34 (The
magnitude and statistical significance of the results were comparable under a linear
regression model.) The unadjusted association between adherence and the demographic,
depression, and substance use variables was examined with logistic regression. Additional
logistic regression models were used to examine subgroup associations between race/
ethnicity and adherence at each level of the other demographic, depression, and substance
use variables.
Because the data originated from multiple studies, we first conducted preliminary analyses
to identify any site-specific associations between the medication adherence outcome and
each of the demographic, depression, and substance variables. For each predictor variable,
the adherence outcome was regressed on site, the predictor, and the predictor × site
interaction in separate models. An omnibus Wald χ2 test of the predictor × site interactions
evaluated whether the relation between the predictor and medication adherence varied by
site. The interaction effect with site was significant for race/ethnicity, age, depression, and
substance use. Consequently, we controlled for the main effect of site and its interactions
with those 4 variables in the final model. Site effects were modeled using a fixed effect
approach because of the small number of clusters and because the sites were not sampled
randomly from all possible locations in the United States. Based on the final model, adjusted
mean adherence was calculated for African American, Latino, and white participants with
all other variables held at their mean levels. In the case of categorical covariates such as
gender, the mean level represented the average proportion of individuals in the respective
categories. Consequently, the adjusted mean reflected a weighted average of adherence
across the different subgroups.
Next, a sequential logistic regression was used to determine if the association of race/
ethnicity with ART adherence would persist after controlling for relevant (1) demographic
and (2) substance use and depression confounders. Omnibus Wald χ2 tests evaluated
whether the variables in each step of the model were collectively associated with medication
adherence. In step 1, race/ethnicity (predictor 1), age in years (2), gender (3), annual
household income (4), and education (5) were entered into the model to account for
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demographic associations with medication adherence. In step 2, substance use (6) and
depression (7) were entered to assess the additional effect of mental health symptoms on
adherence after controlling for demographic factors, site, and the interaction of site with all
predictors that varied by site. As site was not of substantive interest in the final results, we
report the average effect across sites all predictions, weighted by the relative sample size
among the cities included in the analysis.
RESULTS
Participant Characteristics
The final analytic sample of 1809 participants ranged in age from 18 to 72 years and was
mostly (67%) male. Participants were 53% African American (n = 951), 14% Latino (n =
250), and 34% white (n = 608). Although most were well educated (66% had a high school
or general education degree and 11% had a college degree), more than half (59%) reported
an annual household income of less than $10,000. Forty-one percent were heterosexual, 33%
were gay or lesbian, and 14% were bisexual. With respect to baseline medication, 31% of
participants were on a once-daily regimen, 61% were on a twice-daily regimen, and 8%
were on a thrice-daily regimen (Table 1). Regimens were based on a protease inhibitor
(51%), a nucleoside reverse transcriptase inhibitor (29%), a nonnucleoside reverse
transcriptase inhibitor (16%), a nucleotide reverse transcriptase inhibitor (3%), a fusion
inhibitor (<1%), or another medication (<1%).
To assess for differences between participants with complete data (60%), those who were
missing substance use only (2%), depression only (15%), or both substance use and
depression data (23%), χ2 tests and 1-way analyses of variance were conducted on
categorical and continuous demographic characteristics, respectively. There was no racial/
ethnic difference between individuals with complete data and those without. Individuals
with complete data were more likely to have at least a high school diploma [χ2 (2) = 20.39,
P < 0.001], possess a higher annual household income [χ2 (4) = 21.11, P < 0.001], be female
[χ2(1) = 11.22, P = 0.001], and be of older age [F (1,1807) = 18.21, P < 0.001].
Descriptive and Bivariate Analyses
Means, standard deviations, and bivariate correlations of the adherence, demographic,
substance use, and depression variables are presented in Table 1. The mean standardized
depression score was 0.77 (SD = 1.65). Among the subgroup of participants from studies
that used a depression scale with established diagnostic cutoffs (n = 1115), 60% (n = 673)
had none or minimal signs of depression, 25% (n = 282) had mild to moderate depression,
and 14% (n = 160) had severe depressive symptomatology. Among the participants with
substance use data (n = 1364), 65% reported using no substances in the 30–365 days
preceding their baseline assessment, 26% reported using one substance, and 10% reported
using 2 or more substances. African American [35%; χ2 (1) = 6.38, P = 0.01] and Latino
[48%; χ2 (1) = 21.93, P < 0.0001] participants were more likely to report use of at least 1
substance compared with white participants (28%).
Mean adherence levels by race/ethnicity and other prospective predictors are reported in
Table 2. African American (65%), Latino (64%), and white (72%) evidenced an omnibus
difference in mean adherence, χ2 (2) = 22.96, P < 0.001. With respect to bivariate analyses,
all the predictor variables had statistically significant associations with adherence (P < 0.05).
Sequential Logistic Regression
The sequential logistic regression model results are presented in Table 3. The demographic
variables in step 1 were collectively associated with medication adherence [omnibus χ2 (36)
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= 172.32, P < 0.0001]. When controlling for only demographic variables, race/ethnicity was
a significant predictor of ARV medication adherence [omnibus test: χ2 (21) = 119.09, P <
0.0001]. The substance use and depression variables introduced in step 2 improved upon the
prediction of medication adherence [χ2 (24) = 61.94, P < 0.0001]. When controlling for
demographics, substance use, and depression, race/ethnicity remained a significant predictor
of medication adherence [omnibus test: χ2 (21) = 122.10, P < 0.0001].
The relationship between race/ethnicity and adherence was comparable in the model
controlling for only demographic variables (step 1) and the model controlling for
demographics in addition to substance use and depression (step 2). In the full model
controlling for all variables, the odds of 100% medication adherence were 40% lower [odds
ratio (OR) = 0.60, 95% CI: = 0.52 to 0.70, P < 0.001] among African Americans compared
with white participants and 28% lower (OR = 0.72, 95% CI: = 0.53 to 0.98, P = 0.04)
compared with Latino participants. The odds of 100% medication adherence were
comparable among Latinos compared with white participants (OR = 0.84, 95% CI: = 0.61 to
1.15, P = 0.27). Adjusted mean adherence in the full model was 61% among African
Americans (95% CI: = 59% to 64%), 69% among Latinos (95% CI = 63% to 75%), and
72% among white participants (95% CI: = 69% to 75%). Mean adherence among African
Americans was significantly lower than adherence among Latinos (Estimate = −8%, P =
0.04) and whites (Estimate = −11%, P < 0.001). The difference in mean adherence between
Latinos and whites was not statistically significantly (Estimate = 3%, P = 0.27).
DISCUSSION
In this analysis of pooled data from 13 studies in the United States, racial/ethnic disparities
in adherence persisted even after controlling for key demographic variables (ie, sex, age,
income, education, and site), depression, and substance use. The underlying mechanisms
leading to these racial/ethnic disparities remain unclear, although we can speculate based on
the experience of individuals of minority race/ethnicity in the United States.
The marginalization experienced by racial/ethnic minorities is the United States can be
understood as involving overt discrimination as well as “microaggressions”, which are
“brief and commonplace daily verbal, behavioral, or environmental indignities, whether
intentional or unintentional, that communicate hostile, derogatory, or negative racial slights
and insults toward people of color”.35 As discrimination is related to worse health outcomes
and maladaptive health behaviors,36 it may be implicated in worse ART adherence.37 For
example, among 152 HIV-positive African American men who have sex with men, Bogart
et al38 found that 40% reported racial discrimination in the last 6 months, which was
significantly associated in longitudinal analyses with lower adherence. Racial/ethnic
minorities who experience discrimination may find it more difficult to trust their providers, a
distrust which may also negatively impact adherence. For example, Saha et al39 found that
compared with white patients (n = 201), African Americans (n = 1104) expressed lower
levels of trust in their provider, which was associated with worse adherence.
Levels of trust in providers may have a basis in experience. A study of 1886 participants
(54% white, 28% black, 14% Hispanic) from the HIV Cost and Services Utilization Study21
found that 40% reported having a discriminatory health care experience since their HIV
diagnosis and that 24% failed to “completely” or “almost completely” trust their health care
providers. In a structural equation model in the same study, discrimination predicted distrust,
weaker treatment benefit beliefs, and, in turn, poorer adherence. Distrust seemed to operate
on medication adherence by increasing treatment-related psychological distress and
weakening treatment benefit beliefs.
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Related recent work from Bogart et al38 has pointed to conspiracy beliefs as possible
explanations. Among 177 blacks, they identified 2 distinct belief categories: genocidal
beliefs (eg, HIV was created by humans) and treatment-related beliefs (eg, people on ART
are the government’s guinea pigs). Although both genocidal and treatment-related
conspiracy beliefs were related to electronically monitored adherence in univariate analyses,
in multivariate tests only the latter were linked to a lower likelihood of optimal adherence at
1 month. Most of this work has been done with African Americans; more work with Latinos
is needed.
Health literacy is another possible explanation for racial/ethnic disparities in ART
adherence. People with low literacy may not be able to read or identify their medications,
which makes it difficult for them to adhere to their prescribed regimens.40 HIV-positive
African Americans with low levels of educational literacy have been found to be more
nonadherent to ART.41 In addition, Osborn et al42 found that when health literacy was
included as a mediator in their analyses, the association of African American race and worse
4-day self-reported ART adherence was reduced to nonsignificance. More specifically,
Waldrop-Valverde et al22 investigated numeracy or the ability to understand and use
numbers in daily life. They found that poor management of a simulated ARV regimen
among African American men and women with HIV was mediated by lower numeracy.
The current research points to many possible directions for future intervention. As Bogart et
al43 have pointed out, adherence interventions designed to address culturally specific roots
of nonadherence may help to overcome medical mistrust. These might involve culturally
tailored components delivered ideally by peer advocates or community-level interventions
with recognized popular opinion leaders. Also, future work will need to disaggregate the
racial/ethnic categories summarized for convenience here into the broad groupings of
“African Americans” and “Latinos.” Earlier work based on the Multi-site AIDS Cohort
Study, for example, indicated that blacks of Caribbean descent had worse adherence than
those from other regions.12 There may be important Latino subgroup differences as well.
We know of no work that has begun to investigate these differences.
Limitations of the present study include the reliance on self-report measures of depression
and substance use and their lack of uniformity in measurement across studies. For example,
a consistent duration for substance-use assessment across all studies (instead of the actual
range of 30–365 days) would have been preferable but would have necessitated our limiting
the analyses to the few studies that used the same duration for measurement. Our current
analysis represents a conservative estimate of controlling for any substance use at all but
may mask the adherence-reducing effects of more intensive substance use. This could
potentially affect our main findings if this higher severity of substance use was more
common in one racial/ethnic group than another. Our approach to combining the different
depression measures, though recommended per Anastasi,30 is limited by the quality of the
normative estimates available (Wagner et al31) and the degree to which the different scales’
items tapped different aspects of depression. The threat to validity is thought to be minimal;
however, as the norms are based on very large population samples and there is good overlap
of items on these scales. Furthermore, in the prior study we demonstrated that the findings
observed using this approach approximated findings obtained from using a more
conservative approach of converting raw scores using standard cut-offs for mild/moderate/
severe depression across all measures. As such, we are confident in this recoded variable’s
ability to control for the effects of depression in the analyses presented here.
Another limitation is that data on all variables were not available from each study, although
participants with missing data on depression and substance use were retained in the analyses
by creating a category for missing data (ie, a missing indicator approach). A broader
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assessment of mental health would have been helpful, perhaps validated by clinician rating.
Importantly, the MACH14 data set had a limited array of variables available for
investigation. Factors we could not include here—such as self-efficacy, social support,
housing status, food insecurity, or insurance status—may have accounted for the race/
ethnicity and adherence association.
In conclusion, this study of pooled data from 13 different US studies confirmed prior reports
of racial/ethnic disparities in ART adherence, even when adherence was more objectively
measured and analyses adjusted for key demographic variables, substance use, and
depression. The findings may help to explain the worse health outcomes for racial/ethnic
minorities with HIV in the United States and suggest a need for interventions targeting their
adherence to achieve the US National HIV/AIDS Strategy goal to reduce HIV-related health
disparities. There is a need for more research on the mechanisms of these racial/ethnic
disparities to inform intervention development and better address these inequities.
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